Recently, serum-derived exosomal HER2 was found to be a highly specific sentinel molecule to assess tissue HER2 status, with a stable diagnostic effect in patients with advanced GC (n = 238, of which 114 were HER2-positive), and thus screened patients that could potentially benefit from anti-HER2 therapy [188]. The gene discussed is ERBB2; the disease is gastric cancer.